WO1999021988A1 - Gene sec22b humain de cbfbba01 de la proteine d'echange vesiculaire - Google Patents

Gene sec22b humain de cbfbba01 de la proteine d'echange vesiculaire Download PDF

Info

Publication number
WO1999021988A1
WO1999021988A1 PCT/CN1997/000115 CN9700115W WO9921988A1 WO 1999021988 A1 WO1999021988 A1 WO 1999021988A1 CN 9700115 W CN9700115 W CN 9700115W WO 9921988 A1 WO9921988 A1 WO 9921988A1
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptide
cbfbbaol
seq
nucleotide sequence
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN1997/000115
Other languages
English (en)
Inventor
Ji-Sheng Wu
Ya-Xin Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Second Medical University
Original Assignee
Shanghai Second Medical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Second Medical University filed Critical Shanghai Second Medical University
Priority to PCT/CN1997/000115 priority Critical patent/WO1999021988A1/fr
Publication of WO1999021988A1 publication Critical patent/WO1999021988A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Definitions

  • variants are those that vary from the referents by conservative amino acid substitutions - i.e., those that substitute a residue with another of like characteristics. Typical such substitutions are among Ala, Val, Leu and He; among Ser and Thr; among the acidic residues Asp and Glu; among Asn and Gin; and among the basic residues Lys and Arg; or aromatic residues Phe and Tyr. Particularly preferred are variants in which several, 5-10, 1-5, or 1-2 amino acids are substituted, deleted, or added in any combination.
  • host cells can be genetically engineered to incorporate expression systems or portions thereof for polynucleotides of the present invention.
  • Introduction of polynucleotides into host cells can be effected by methods described in many standard laboratory manuals, such as Davis et al. , BASIC METHODS LN MOLECULAR BIOLOGY (1 86) and Sambrook et al., MOLECULAR CLONING: A LABORATORY MANUAL, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989) such as calcium phosphate transfection, DEAE-dextran mediated transfection, transvection, microinjection, cationic lipid-mediated transfection, electroporation, transduction, scrape loading, ballistic introduction or infection.
  • the genomic DNA may be used directly for detection or may be amplified enzymatically by using PCR or other amplification techniques prior to analysis.
  • RNA or cDNA may also be used in similar fashion. Deletions and insertions can be detected by a change in size of the amplified product in comparison to the normal genotype. Point mutations can be identified by hybridizing amplified DNA to labeled CBFBBAOl nucleotide sequences. Perfectly matched sequences can be distinguished from mismatched duplexes by RNase digestion or by differences in melting temperatures. DNA sequence differences may also be detected by alterations in electrophoretic mobility of DNA fragments in gels, with or without denaturing agents, or by direct DNA sequencing. See, e.g., Myers et al.
  • the nucleotide sequences of the present invention are also valuable for chromosome identification.
  • the sequence is specifically targeted to and can hybridize with a particular location on an individual human chromosome.
  • the mapping of relevant sequences to chromosomes according to the present invention is an important first step in correlating those sequences with gene associated disease. Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. Such data are found, for example, in V. McKusick, Mendelian Inheritance in Man (available on line through Johns Hopkins).
  • the differences in the cDNA or genomic sequence between affected and unaffected individuals can also be determined. If a mutation is observed in some or all of the affected individuals but not in any normal individuals, then the mutation is likely to be the causative agent of the disease.
  • composition which, when introduced into a mammalian host, induces an immunological response in that mammal to a CBFBBAOl polypeptide wherein the composition comprises a CBFBBAOl polypeptide or CBFBBAOl gene.
  • the vaccine formulation may further comprise a suitable carrier. Since CBFBBAOl polypeptide may be broken down in the stomach, it is preferably administered parenterally (including subcutaneous, intramuscular, intravenous, intradermal etc. injection).
  • This invention provides methods of treating abnormal conditions such as, cancer, autoimmune disease, diabetes mellitus, and multiple sclerosis, related to both an excess of and insufficient amounts of CBFBBAOl polypeptide activity.
  • expression of the gene encoding endogenous CBFBBAOl polypeptide can be inhibited using expression blocking techniques.
  • Known such techniques involve the use of antisense sequences, either internally generated or separately administered. See, for example, O'Connor, J Neurochem (1991) 56:560 in Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression. CRC Press, Boca Raton, FL (1988).
  • oligonucleotides which form triple helices with the gene can be supplied. See, for example, Lee et al, Nucleic Acids Res (1979) 3:173; Cooney et al, Science (1988) 241:456; Dervan et al, Science (1991) 251:1360. These oligomers can be administered per se or the relevant oligomers can be expressed in vivo.
  • systemic administration of the pharmaceutical compositions include injection, typically by intravenous injection.
  • Other injection routes such as subcutaneous, intramuscular, or intraperitoneal, can be used.
  • Alternative means for systemic administration include transmucosal and transdermal administration using penetrants such as bile salts or fusidic acids or other detergents.
  • penetrants such as bile salts or fusidic acids or other detergents.
  • oral administration may also be possible.
  • Administration of these compounds may also be topical and/or localized, in the form of salves, pastes, gels and the like.
  • the dosage range required depends on the choice of peptide, the route of administration, the nature of the formulation, the nature of the subject's condition, and the judgment of the attending practitioner. Suitable dosages, however, are in the range of 0.1-100 ⁇ g/kg of subject. Wide variations in the needed dosage, however, are to be expected in view of the variety of compounds available and the differing efficiencies of various routes of administration. For example, oral administration would be expected to require higher dosages than administration by intravenous injection. Variations in these dosage levels can be adjusted using standard empirical routines for optimization, as is well understood in the art.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des polypeptides et des polynucléotides CBFBBA01 et des procédés de production de ces polypeptides par des techniques recombinantes. Font aussi l'objet de cette invention des procédés d'utilisation des polypeptides et des polynucléotides CBFBBA01 dans la conception de protocoles pour le traitement du cancer, de maladies auto-immunes, du diabète sucré et de la sclérose en plaques, entre autres, et des doses diagnostiques pour ces pathologies.
PCT/CN1997/000115 1997-10-29 1997-10-29 Gene sec22b humain de cbfbba01 de la proteine d'echange vesiculaire Ceased WO1999021988A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/CN1997/000115 WO1999021988A1 (fr) 1997-10-29 1997-10-29 Gene sec22b humain de cbfbba01 de la proteine d'echange vesiculaire

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN1997/000115 WO1999021988A1 (fr) 1997-10-29 1997-10-29 Gene sec22b humain de cbfbba01 de la proteine d'echange vesiculaire

Publications (1)

Publication Number Publication Date
WO1999021988A1 true WO1999021988A1 (fr) 1999-05-06

Family

ID=4574996

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN1997/000115 Ceased WO1999021988A1 (fr) 1997-10-29 1997-10-29 Gene sec22b humain de cbfbba01 de la proteine d'echange vesiculaire

Country Status (1)

Country Link
WO (1) WO1999021988A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001066769A1 (fr) * 2000-03-10 2001-09-13 Shanghai Biowindow Gene Development Inc. Nouveau polypeptide, yip1p28 humaine, et polynucleotide codant pour ce polypeptide
WO2006081331A3 (fr) * 2005-01-25 2007-06-07 Prolexys Pharmaceuticals Inc Erastine et proteines de liaison d'erastine, et utilisations de celles-ci
US7358262B2 (en) 2003-01-29 2008-04-15 Whitehead Institute For Biomedical Research Identification of genotype-selective anti-tumor agents

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANNUAL MEETING OF THE 6TH INTERNATIONAL CONGRESS ON CELL BIOLOGY AND THE 36TH AMERICAN SOCIETY FOR CELL BIOLOGY, SAN FRANCISCO, CALIFORNIA, USA, 7-11 December 1996, MOLECULAR BIOLOGY OF THE CELL 7 (SUPPL.), 1996, 74A, HAY J.C. et al., "Mammalian Vesicle Trafficking Proteins of the Endoplasmic Reticulum and Golgi". *
ANNUAL MEETING OF THE 6TH INTERNATIONAL CONGRESS ON CELL BIOLOGY AND THE 36TH AMERICAN SOCIETY FOR CELL BIOLOGY, SAN FRANCISCO, CALIFORNIA, USA, 7-11 December 1996, MOLECULAR BIOLOGY OF THE CELL 7 (SUPPL.), 1996, 82A, YOON Y., McNIVEN M.A., "Identification of a Novel Dynamin-Like Protein Expressed in Rat Tissues". *
CELL, 89(1), 1997, HAY J.C. et al., "Protein Interactions Regulating Vesicle Transport Between the Endoplasmic Reticulum and Golgi Apparatus in Mammalian Cells", pages 149-158. *
JOURNAL OF BIOLOGICAL CHEMISTRY, 271(10), 1996, HAY J.C. et al., "Mammalian Vesicle Trafficking Proteins of the Endoplasmic Reticulum and Golgi Apparatus", pages 56771-56779. *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001066769A1 (fr) * 2000-03-10 2001-09-13 Shanghai Biowindow Gene Development Inc. Nouveau polypeptide, yip1p28 humaine, et polynucleotide codant pour ce polypeptide
US7358262B2 (en) 2003-01-29 2008-04-15 Whitehead Institute For Biomedical Research Identification of genotype-selective anti-tumor agents
US8124365B2 (en) 2003-01-29 2012-02-28 Whitehead Institute For Biomedical Research Identification of genotype-selective anti-tumor agents
WO2006081331A3 (fr) * 2005-01-25 2007-06-07 Prolexys Pharmaceuticals Inc Erastine et proteines de liaison d'erastine, et utilisations de celles-ci
US7615554B2 (en) 2005-01-25 2009-11-10 Prolexys Pharmaceuticals, Inc. Erastin and erastin binding proteins, and uses thereof
US8518959B2 (en) 2005-01-25 2013-08-27 Prolexys Pharmaceuticals, Inc. Quinoxaline derivatives as antitumor agents

Similar Documents

Publication Publication Date Title
US6319688B1 (en) Polynucleotide encoding human sodium dependent phosphate transporter (IPT-1)
WO1999021991A1 (fr) Bmzf12: gene a doigt de zinc clone a partir de la moelle osseuse
EP0848062A2 (fr) Protéase aspartique ASP1
EP0897002A2 (fr) U62317, une protéine avec un domaine se liant à JNK
EP0854191A2 (fr) Protéine humaine du type cardiac/cerveau-tolloid
EP0846764A2 (fr) Famille de facteurs alpha neurotrophiques des cellules gliales
EP0894855A2 (fr) Facteur de transcription I kappa B-beta humain
US5837508A (en) Membrane-type matrix metalloproteinase-5 gene
US6187908B1 (en) Tubby 2 polypeptides
WO2000026374A2 (fr) Proteine specifique adipeuse
US6657047B2 (en) Human Pelota homolog
EP0881294A2 (fr) HOEFCC11, variante d'épissure de HAS2
CA2230996A1 (fr) Composes nouveaux
EP0897982A2 (fr) Co-transporteurs de bicarbonate de sodium
EP0894856A1 (fr) Variante d'épissure de sMAD3 humaine
WO1999022006A1 (fr) Cblafc02: sous-unite de h(+)-atpase vacuolaire
WO1999021885A1 (fr) Gene transporteur 7 abc humain (habc7)
US20020019520A1 (en) CBFBGA09: a human SL15 homolog
EP0879886A2 (fr) HLDAT86, Protéine de la transduction de signaux et homoloque humaine de Wnt-4
WO1999046290A1 (fr) Gene humain de type recepteur d'angiotensine ii/vasopreessine (aii/avp) (cbdakd01)
WO1999021982A1 (fr) Gene m6b1 humain
WO1999036523A1 (fr) Gene semblable a golgi v-snare (gos-28) de rats (cblalg01)
EP0844253A1 (fr) Polynucléotides et polypeptides appartenant à la famille "Tubby"
EP0897979A2 (fr) Clone de cADN SDR2 humaine
WO1999036522A1 (fr) Gene a faible similitude avec la tropomyosine (cbcadb07)

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 09011383

Country of ref document: US

AK Designated states

Kind code of ref document: A1

Designated state(s): CA CN JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase